Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil (MMF) (CellCept®) and Sirolimus (Rapamune®)

NCT00121810 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00121810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00121810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil (MMF) (CellCept®) and Sirolimus (Rapamune®)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2003
Completion date
November 30, 2009
Enrollment
305 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation